Latest News and Press Releases

All 84 sites for pivotal Phase 3 study in early AD are now fully activated, and the first group of patients has completed the 6-month treatment period.

AC Immune Reports Second Quarter 2025 Financial Results and Provides a Corporate Update Three active immunotherapies for precision prevention of neurodegeneration progressing through Phase 2 clinical...

NEW YORK, July 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...

Inflammasome-driven microglial inflammation key to accumulation of toxic phosphorylated alpha-synuclein leading to neurodegeneration and Parkinson's.

Data published in Obesity journal show enhanced weight loss effect of NT-0796 when combined with semaglutide in preclinical obesity modelObese state completely reversed with 30% weight loss and...

AC Immune Reports First Quarter 2025 Financial Results and Provides a Corporate Update Continuing to advance clinical active immunotherapy portfolio for precision prevention of neurodegenerative...

ZyVersa's IC 100 blocked microglial NLRP1 inflammasome activation and reduced alpha-synuclein accumulation supporting its potential for Parkinson's Disease

New research suggests amyloid β and BACE1 may protect the brain by binding toxic metals, rather than causing Alzheimer’s.

Dublin, March 03, 2025 (GLOBE NEWSWIRE) -- The "Neurology Market: Research Overview" report has been added to ResearchAndMarkets.com's offering.The Neurology Market was valued at USD 67.3 Billion...

NEW YORK, Feb. 21, 2025 (GLOBE NEWSWIRE) -- Tiziana Life Sciences, Ltd. (Nasdaq: TLSA) (“Tiziana” or the “Company”), a biotechnology company developing breakthrough immunomodulation therapies with...